Palliative Radiotherapy for Diffuse Large B-cell Lymphoma

Wright, Christopher M.; Koroulakis, Antony; Baron, Jonathan; Chong, Elise A.; Tseng, Yolanda D.; Kurtz, Goldie; LaRiviere, Michael J.; Venigalla, Sriram; Jones, Joshua; Maity, Amit; Mohindra, Pranshu; Plastaras, John P.; Paydar, Ima

doi:10.1016/j.clml.2021.05.007

Cited by 8 publications

(2 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings demonstrate that RT can be an important treatment option following CAR T-cell therapy failure, aligning with previous series that support the use of RT for relapse after primary therapy of DLBCL. 29 , 30 …”

Section: Discussionmentioning

confidence: 99%

Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy

Ababneh

Frigault

et al. 2023

haematol

View full text Add to dashboard Cite

Despite the success of CAR T-cell therapy in patients with relapsed/refractory large- B cell lymphoma (LBCL), there is a need for effective salvage strategies post-CD19-targeted chimeric antigen receptor (CAR T)-cell therapy failure. We conducted a multi-institutional retrospective study of patients who relapsed following CAR T-cell therapy [axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel)] and received salvage therapies [RT alone, systemic therapy alone, or combined modality therapy (CMT)]. A total of 120 patients with post-CAR T relapsed LBCL received salvage therapies (RT alone, 25 patients; CMT, 15 patients; systemic therapy alone, 80 patients). The median follow-up from CAR T-cell infusion was 10.2 months [interquartile range (IQR): 5.2-20.9 months]. Failure occurred in previously involved sites prior to CAR T-cell therapy in 78% of patients (n=93). A total of 93 sites were irradiated in 54 patients who received any salvage RT post-CAR T failure. The median dose/fractionation were 30 Gy (range, 4-50.4 Gy) and 10 fractions (range, 1-28 fractions). The 1-year local control (LC) rate for the 81 assessable sites was 84%. On univariate analysis, the median OS from the start date of RT was significantly higher among patients who received comprehensive RT vs focal RT (19.1 months vs. 3.0 months, p=

show abstract

Section: Discussionmentioning

confidence: 99%

Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy

Ababneh

Frigault

et al. 2023

haematol

View full text Add to dashboard Cite

show abstract

“…If it is a primary extranodal-involved DLBCL, chemotherapy or a combination of surgery with radiotherapy (RT) can be considered as an option. In recent studies, hypofractionated RT and low-dose RT have been used to treat recurrent tumors of DLBCL in need of palliation [ 13 ]. At the molecular level, it is known that the specific gene expressions can predict the prognosis of DLBCL; for example, the expression of both MYC and BCL2 (“dual-expresser”) by immunohistochemical staining has been associated with poor prognosis [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

Hepatic Involvement of Diffuse Large B-Cell Lymphoma Mimicking Antinuclear Antibody-Negative Autoimmune Hepatitis Diagnosed by Liver Biopsy

et al. 2022

View full text Add to dashboard Cite

Non-Hodgkin’s lymphoma (NHL) is the fifth most common hematologic disorder in the United States, and its prevalence has been rising in Western countries. Among the subtypes of NHL, diffuse large B-cell lymphoma (DLBCL) mostly involves the lymph nodes, stomach, and gastrointestinal tract, whereas hepatic involvement of DLBCL is rare. On serologic testing, elevated immunoglobulin G (IgG) levels can be observed in DLBCL; however, elevated IgG levels are mainly observed in autoimmune hepatitis. A targeted-lesion biopsy is required for the diagnosis of DLBCL. Based on a final diagnosis, the patient was treated with rituximab-based chemotherapy, including cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (R-CHOP). Herein, we report a case of DLBCL mimicking antinuclear antibody-negative autoimmune hepatitis, which was finally diagnosed as DLBCL involving the liver, and was confirmed by liver biopsy.

show abstract

Role of Radiomics-Based Baseline PET/CT Imaging in Lymphoma: Diagnosis, Prognosis, and Response Assessment

Jiang

et al. 2022

Mol Imaging Biol

View full text Add to dashboard Cite

Palliative Radiotherapy for Diffuse Large B-cell Lymphoma

Cited by 8 publications

References 77 publications

Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy

Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy

Hepatic Involvement of Diffuse Large B-Cell Lymphoma Mimicking Antinuclear Antibody-Negative Autoimmune Hepatitis Diagnosed by Liver Biopsy

Role of Radiomics-Based Baseline PET/CT Imaging in Lymphoma: Diagnosis, Prognosis, and Response Assessment

Contact Info

Product

Resources

About